Omer Faruk ERCEYLAN, Ayse SAVAS, Esra GOV

Targeting the tumor stroma: integrative analysis reveal GATA2 and TORYAIP1 as novel prognostic targets in breast and ovarian cancer

Tumor stroma interaction is known to take a crucial role in cancer growth and progression. In the present study, it was performed gene expression analysis of stroma samples with ovarian and breast cancer through an integrative analysis framework to identify common critical biomolecules at multiomics levels. Gene expression datasets were statistically analyzed to identify common differentially expressed genes (DEGs) by comparing tumor stroma and normal stroma samples. The integrative analyses of DEGs indicated that there were 59 common core genes, which might be feasible to be potential marks for cancer stroma targeted strategies. Reporter molecules (i.e. receptor, transcription factors and miRNAs) were determined through a statistical test employing the hypergeometric probability density function. Afterward, the tumor microenvironment protein-protein interaction and the generic network were reconstructed by using identified reporter molecules and common core DEGs. Through a systems medicine approach, it was determined that hub biomolecules, AR, GATA2, miR-124, TOR1AIP1, ESR1, EGFR, STAT1, miR-192, GATA3, COL1A1, in tumor microenvironment generic network. These molecules were also identified as prognostic signatures in breast and ovarian tumor samples via survival analysis. According to literature searching, GATA2 and TORYAIP1 might represent potential biomarkers and candidate drug targets for the stroma targeted cancer therapy applications.

Keywords:

Gene expression cancer stroma, biomarkers, network medicine,

PDF

___

Agostini A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29332-7
Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250
Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438
Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003
Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
Calimlioglu B, 2015, OMICS, V19, P563, DOI 10.1089/omi.2015.0088
Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8
Chen HJ, 2018, INT J CANCER, V143, P3106, DOI 10.1002/ijc.31750
Comertpay B, 2020, AUTOIMMUNITY, V53, P156, DOI 10.1080/08916934.2020.1722107
Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
Erez N, 2013, BIOCHEM BIOPH RES CO, V437, P397, DOI 10.1016/j.bbrc.2013.06.089
Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
Giannopoulou L, 2018, GYNECOL ONCOL, V150, P355, DOI 10.1016/j.ygyno.2018.05.026
Giovannelli P, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00492
Gov E, 2020, SYST BIOL REPROD MED, V66, P255, DOI 10.1080/19396368.2020.1759730
Gov E, 2017, OMICS, V21, P603, DOI 10.1089/omi.2017.0115
Gov E, 2017, SYST BIOL REPROD MED, V63, P219, DOI 10.1080/19396368.2017.1330368
Guo S, 2018, INT J BIOL SCI, V14, P2083, DOI 10.7150/ijbs.25720
Henshall SM, 2001, CANCER RES, V61, P423
Hu F, 2013, BBA-MOL BASIS DIS, V1832, P2379, DOI 10.1016/j.bbadis.2013.08.011
Islam T, 2018, OMICS, V22, P422, DOI 10.1089/omi.2018.0048
Josahkian JA, 2018, INT J GYNECOL CANCER, V28, P459, DOI 10.1097/IGC.0000000000001193
Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055
Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
Karagoz K, 2016, J THEOR BIOL, V403, P85, DOI 10.1016/j.jtbi.2016.05.020
Karn T, 2015, CURR CANCER DRUG TAR, V15, P652, DOI 10.2174/156800961508151001101209
Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
Kori M, 2016, SYST BIOL REPROD MED, V62, P266, DOI 10.1080/19396368.2016.1197982
Koromilas Antonis E, 2013, JAKSTAT, V2, pe23353, DOI 10.4161/jkst.23353
Li MY, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112153
Lili LN, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/846387
Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3
Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y
Planche A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018640
Rahman MR, 2020, GENOMICS, V112, P1290, DOI 10.1016/j.ygeno.2019.07.018
Safran M, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq020
Schauer IG, 2011, NEOPLASIA, V13, P393, DOI 10.1593/neo.101720
Sevimoglu T, 2014, COMPUT STRUCT BIOTEC, V11, P22, DOI 10.1016/j.csbj.2014.08.008
Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425
Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
Smyth GK, 2003, BIOINFORMATICS, V20, P3705
TONG CWS, 2018, ONCOLOGY-BASEL, V8, DOI DOI 10.3389/FONC.2018.00227
Uddin MN, 2019, J ONCOL, V2019, DOI 10.1155/2019/8752862
Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1
Wang YB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2862-4
Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023
Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
Zellmer VR, 2017, MOL CANCER RES, V15, P585, DOI 10.1158/1541-7786.MCR-16-0312
Zhao Y, 2017, ONCOTARGET, V8, P25005, DOI 10.18632/oncotarget.15334